Related references
Note: Only part of the references are listed.Regulation of the human TRAIL gene
Joshua E. Allen et al.
CANCER BIOLOGY & THERAPY (2012)
Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
Joshua E. Allen et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Hiromichi Ebi et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Loss of memory B cells during chronic HIV infection is driven by Foxo3a-and TRAIL-mediated apoptosis
Julien Van Grevenynghe et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Theonie Anastassiadis et al.
NATURE BIOTECHNOLOGY (2011)
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
T. Trarbach et al.
BRITISH JOURNAL OF CANCER (2010)
Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer
Jer-Yen Yang et al.
CANCER RESEARCH (2010)
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
TRAIL receptor signaling and therapeutics
Junaid Abdulghani et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
A Better TRAIL Variant for Tumor Cell-Specific Targeting? - Letter
Edwin Bremer et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells
Soo-Jung Park et al.
CELLULAR SIGNALLING (2009)
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Constantijne H. Mom et al.
CLINICAL CANCER RESEARCH (2009)
Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
Stephen Leong et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy
Lata G. Menon et al.
STEM CELLS (2009)
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death
Kageaki Kuribayashi et al.
CANCER BIOLOGY & THERAPY (2008)
Synthesis of new pyrrolo[1,2-a]quinoxaline derivatives as potential inhibitors of Akt kinase
Vanessa Desplat et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2008)
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
F. Anthony Greco et al.
LUNG CANCER (2008)
ERK and MDM2 prey on FOXO3a
Wensheng Yang et al.
NATURE CELL BIOLOGY (2008)
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
Jer-Yen Yang et al.
NATURE CELL BIOLOGY (2008)
FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells
A. N. Cornforth et al.
ONCOGENE (2008)
Role of tumor necrosis factor-α and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma
Mohammed M. Shareef et al.
CANCER RESEARCH (2007)
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2007)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts
Wenge Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
FOXO transcription factors at the interface between longevity and tumor suppression
EL Greer et al.
ONCOGENE (2005)
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
A Nebbioso et al.
NATURE MEDICINE (2005)
IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a
MCT Hu et al.
CELL (2004)
Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human Esophageal epithelial cells
SH Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Activating FOX03a, NF-κB and p53 by targeting IKKs -: An effective multi-faceted targeting of the tumor-cell phenotype?
N Finnberg et al.
CANCER BIOLOGY & THERAPY (2004)
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy
SL Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells
TR Kau et al.
CANCER CELL (2003)
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOX03a transcription factor
S Ghaffari et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression -: Implications for PTEN mutation in prostate cancer
V Modur et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
NATURE REVIEWS CANCER (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Share Paper
